# 510(k) Summary

# LIAISON® N-TACT® PtH Gen II LIAISON® N-TACT® PTH Gen II ContrOl Set LIAISON® N-TACT® PTH Gen II Calibration Verifiers

This summary of $5 1 0 ( k )$ safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

1. 510(k) Number: k132515

2. Applicant: Carol A. DePouw DiaSorin Inc. 1951 Northwestern Avenue, P.O. Box 285, Stillwater, MN 55082-0285 Office Number: 651-351-5850; Fax Number: 651-351-5669 Email: carol.depouw@diasorin.com

3. Date: September 4, 2013

# 4. Proprietary and Established Names:

LIAISON® N-TACT PTH Gen II LIAISON® N-TACT® PTH Gen II Control Set LIAISON® N-TACT® PTH Gen II Calibration Verifiers

NOV 0 8 2013

# 5. Regulatory Information:

LIAISON® N-TACT® PTH Gen II

Regulation Section: 21 CFR 862.1545   
Classification: Class II   
Product Code: CEW   
Panel: Clinical Chemistry (75)

LIAISON® N-TACT® PTH Gen II Control Set LIAISON® N-TACT® PTH Gen II Calibration Verifiers

Regulation Section: 21 CFR 862.1660 Classification: Class I, reserved Product Code: JJX Panel: Clinical Chemistry (75)

# Predicate Devices:

The predicate device used to demonstrate substantial equivalence to the LIAlSON® N-TACT PTH n    ADVIA ENTAUR INTACT (iPTH) Assay previously cleared under k020217.

The predicate device used to demonstrate substantial equivalence to the LIAlSON® N-TACT® TH Gen II Conrol Set is the LIAISON® N-TACT® PTH Conrol Set previuSy cleared under k033426.

The predicate device used to demonstrate substantial equivalence to the LIAlSON® N-TACT® PTH Gen II Calibration Verifiers is the LIAISON® N-TACT® PTH Calibration Verifiers previously cleared under k093498.

# 7Device Description:

The LIAISON® N-TACT® PTH Gen I assay is a modified two-step, two-site sandwich assay that uses two goat polyclonal antibodies for capture and detection of intact PTH. Results are determined by a 2 point calibration conversion of the master curve to a working curve. The light signal is measured by a photomultiplier as relative light units (RLU) and is proportional to the concentration of intact PTH present in the calibrators, controls or samples.

LIAISON® N-TACT® PTH Gen II Control set contains;

2 levels controls containing $80 \%$ human plasma spiked with 1-84 PTH, and preservatives; 4 vials each level; lyophilized

The target concentration for control level 1 is 20 pg/mL. The target concentration for control Level 2 is $3 0 0 p g / m L$

The range of concentrations of each control is reported on the certificate of analysis provided with each LIAISON® N-TACT® PTH Gen II Control set.

LIAISON® N-TACT® PTH Gen II Calibration Verifier set contains:

4 levels containing $80 \%$ human plasma spiked with 1-84 PTH, with preservative, 1 vial each level, lyophilized

The target concentration for cal verifier A is $1 0 \ p g / m L$ .   
The target concentration for cal verifier B is 150 pg/mL.   
The target concentration for cal verifier C is 650 pg/mL.   
The target concentration for cal verifier D is 1600 pg/mL.

The range of concentrations of each calibration verifier is reported on the certificate of analysis provided with each LIAISON® N-TACT® PTH Gen II Calibration Verifier set.

# 8. Intended Use:

The LIAISON® N-TACT® PTH Gen II is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of intact human parathyroid hormone in serum, EDTA and Lithium Heparin plasma samples. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from disorders of calcium metabolism.

The s is  e peo on he LAI® Ana.

The LIAISON® N-TACT® PTH Gen Il Control Set is intended for use as assayed quality control samples to monitor the accuracy and precision of the DiaSorin LIAlSON® N-TACT® PTH Gen I assay.

The LIAISON® N-TACT® PTH Gen II Calibration Verifiers are assayed quality control materials intended for the quantitative verification of calibration and reportable range of the LIAISON® N-TACT® PTH Gen II assay.

9. Indication(s) for Use:

Same as Intended Use

# 10. Substantial Equivalence Information:

Both the LIAISON® N-TACT® PTH Gen II and the predicate Siemens ADVIA CENTAUR® INTACT Parathyroid Hormone (iPTH) Assay are prepackaged reagents for use on automated clinical chemistry analyzers. A comparison of the similarities and differences between the devices are provided in the following table:

<table><tr><td colspan="3" rowspan="1">Assay Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Candidate DeviceLIAISON® N-TACT® PTH GeN II</td><td colspan="1" rowspan="1">Predicate DeviceADVIA Centaur iPTH (K020217)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For in vitro quantitative determinationof intact human parathyroid hormone</td><td colspan="1" rowspan="1">For in vitro quantitative determinationof intact parathyroid hormone</td></tr><tr><td colspan="1" rowspan="1">Measured Analyte</td><td colspan="1" rowspan="1">Intact Parathyroid Hormone</td><td colspan="1" rowspan="1">Intact Parathyroid Hormone</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Two-point calibration</td><td colspan="1" rowspan="1">Two-point calibration</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">Goat polyclonal</td><td colspan="1" rowspan="1">Goat polyclonal</td></tr><tr><td colspan="1" rowspan="1">Reagent Storage</td><td colspan="1" rowspan="1">On-board or in refrigerator @ 2-8°</td><td colspan="1" rowspan="1">On-board or in refrigerator @ 2-8°</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">3 - 1900 pg/mL</td><td colspan="1" rowspan="1">2.5 - 1900 pg/mL</td></tr><tr><td colspan="1" rowspan="1">Sample Matrix</td><td colspan="1" rowspan="1">EDTA Plasma, Serum, SST serumand Lithium Heparin plasma</td><td colspan="1" rowspan="1">EDTA.Plasma and Serum</td></tr><tr><td colspan="1" rowspan="1">Sample size</td><td colspan="1" rowspan="1">150 μL</td><td colspan="1" rowspan="1">200 μL</td></tr><tr><td colspan="1" rowspan="1">Open storageon analyzer</td><td colspan="1" rowspan="1">56 days</td><td colspan="1" rowspan="1">28 days</td></tr><tr><td colspan="1" rowspan="1">Calibration interval</td><td colspan="1" rowspan="1">28 days</td><td colspan="1" rowspan="1">14 days</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">2 levels - Included with kit</td><td colspan="1" rowspan="1">2 Levels - Not included with kit</td></tr><tr><td colspan="1" rowspan="1">ManufacturersControls</td><td colspan="1" rowspan="1">2 levels</td><td colspan="1" rowspan="1">3 levels</td></tr><tr><td colspan="1" rowspan="1">Reference range</td><td colspan="1" rowspan="1">14.5 - 87.1 pg/mL</td><td colspan="1" rowspan="1">11.1 - 79.5 pg/mL</td></tr><tr><td colspan="3" rowspan="1">Control Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Candidate DeviceLIAISON® N-TACT PTH GeN IIControl Set</td><td colspan="1" rowspan="1">Predicate DeviceLIAISON® N-TACT® PTHControl Set (k033426)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">intended for use as assayed qualitycontrol samples to monitor theaccuracy and precision of theLIAISON® N-TACT PTH Gen II</td><td colspan="1" rowspan="1">intended for use as assayed qualitycontrol samples to monitor theaccuracy and precision of theLIAISON® N-TACT PTH</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Store at 2-8°C until ready to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Levels</td><td colspan="1" rowspan="1">2 levels: lyophilizedLevel 1 (approx 20 pg/mL)Level 2 (approx 300 pg/mL)</td><td colspan="1" rowspan="1">2 levels: lyophilizedLevel 1 (approx 60 pg/mL)Level 2 (approx 560 pg/mL</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Calibration Verifiers Similarities and Differences</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Candidate DeviceLIAISON® N-TACT® PTH GeN IICalibration Verifiers</td><td rowspan=1 colspan=1>Predicate DeviceLIAISON® N-TACT® PTHCalibration Verifiers (k093498)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>assayed quality control materialsintended for the quantitativeverification of calibration andreportable range of the LIAISON®N-TACT PTH Gen II</td><td rowspan=1 colspan=1>assayed quality control materialsintended for the quantitativeverification of calibration andreportable range of the LIAISON®N-TACT PTH</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2 to 8C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>4 levels; lyophilizedCal Ver A (approx 10 pg/mL)Cal Ver B (approx 150 pg/mL)Cal Ver C (approx 650 pg/mL)Cal Ver D (approx 1600 pg/mL)</td><td rowspan=1 colspan=1>4 levels; lyophilizedCal Ver A (approx 20 pg/mL)Cal Ver B (approx 150 pg/mL)Cal Ver C (approx 350 pg/mL)Cal Ver D (approx 1500 pg/mL)</td></tr><tr><td rowspan=1 colspan=1>Volume</td><td rowspan=1 colspan=1>2.0 mLs</td><td rowspan=1 colspan=1>Same</td></tr></table>

# 11.Standard/guidance Document Reference:

CLSI Guideline EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods;   
O C Guidel - Evaluation Linearity QuantitativAnalytical Metos;   
O CLSI Guideline EP7-A2, Interference Testing in Clinical Chemistry:   
0 CLSI Guideline EP9-A2-IR, Method Comparison and Bias Estimation Using Patient Samples; CLSI Guideline EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; CLSI Guideline C28-A3, Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory.

# 12.Performance Characters:

Method Comparison A method comparison study was performed following CLSI EP9-A2, individual results for the Siemens ADVIA Centaur® Intact PTH (iPTH) and the LIAISON® N-TACT® PTH

Gen Il were plotted. Passing & Bablok linear regression analyses were performed and gave the following results:

<table><tr><td rowspan=1 colspan=6>Passing &amp; Bablok Fit</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Interceptpg/mL</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Correlationcoefficient (r).</td></tr><tr><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>1.010</td><td rowspan=1 colspan=1>0.99 to 1.03</td><td rowspan=1 colspan=1>-1.5851</td><td rowspan=1 colspan=1>-3.11 to -0:44</td><td rowspan=1 colspan=1>0.9953</td></tr></table>

# Sample Matrix Comparison

Sixty-five (65) matched patient sets of EDTA plasma, serum, SST serum, and Lithium Heparin plasma samples were tested to determine if these sample types provide ivalent results on e LIAISON® N-TACT® H Gen I assay. The following Passing & Bablok linear regression results were obtained:

<table><tr><td rowspan=1 colspan=1>EDTA plasma vs.</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Interceptpg/mL</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>R^{2$</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.94 to 1.0</td><td rowspan=1 colspan=1>-2.45</td><td rowspan=1 colspan=1>-4.05 to -1.51</td><td rowspan=1 colspan=1>0.9986</td></tr><tr><td rowspan=1 colspan=1>SST Serum</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.99 to 1.03</td><td rowspan=1 colspan=1>-2.25</td><td rowspan=1 colspan=1>-3.10 to -1.44</td><td rowspan=1 colspan=1>0.9996</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.97 to 1.01</td><td rowspan=1 colspan=1>-0.01</td><td rowspan=1 colspan=1>-1.05 to 0.74</td><td rowspan=1 colspan=1>0.9991</td></tr></table>

# Reference Range

EDTA plasma samples from125 apparently healthy adults aged 21 - 70 years of age from mixed ethnic backgrounds $( 3 2 . 5 \%$ dark -skinned, $6 6 . 7 \%$ light-skinned and $0 . 8 \%$ unknown) with normal Total Calcium, TSH, Phosphorus, Magnesium, Creatinine, Alkaline Phosphatase and 25 OH Vitamin D values from the northern and southern regions of the U.S.

LIAISON® N-TACT® PTH Gen II Reference Range   

<table><tr><td rowspan=1 colspan=1>Population(n =125)</td><td rowspan=1 colspan=1>MedianPTH (pg/mL)</td><td rowspan=1 colspan=1>Observed Range2.5th to 97.5thPercentile</td></tr><tr><td rowspan=1 colspan=1>United States</td><td rowspan=1 colspan=1>34.00</td><td rowspan=1 colspan=1>14.5 - 87.1 pg/mL</td></tr></table>

# Precision

Precision testing was performed following CLSI Guideline EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second Edition. A coded panel comprised of 7 frozen EDTA plasma samples spanning th ssay range and 2 lots of LAISON® N-TACT® PTH Gen I conrols (2 levels) w tested in the study. The precision panel samples and kit controls were tested on two lots LA® -TAC H Gen  in tw eplt     r ay  0 operating days for a total of 160 replicate results per sample. The 20 day results are summarized for the combined reagent lot numbers as sample mean PTH concentration in pg/mL, standard deviations and coefficient of variation $( \% C V )$ for between lot and Total across lots.

<table><tr><td rowspan=2 colspan=1>Sample ID</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>MeanPTH(pg/mL)</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total(Across Lots)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Lot 1 Kit Control Level 1</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>19.3</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Lot 1 Kit Control Level 2</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>9.27</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>8.84</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Lot 2 Kit Control Level 1</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>18.5</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td rowspan=1 colspan=1>Lot 2 Kit Control Level 2</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>10.59</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>9.05</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 1</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>4.2%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 2</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>34.5</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>4.0%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 3</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>86.2</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.07</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 4</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>156.1</td><td rowspan=1 colspan=1>5.25</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>5.54</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 5</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>605</td><td rowspan=1 colspan=1>24.62</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>19.37</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 6</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>1348</td><td rowspan=1 colspan=1>46.58</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>44.06</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>EDTA Plasma 7</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>1477</td><td rowspan=1 colspan=1>84.06</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>40.62</td><td rowspan=1 colspan=1>2.8%</td></tr></table>

# Linearity

One sample pool of each type; serum, SST serum, EDTA plasma and Lithium Heparin plasma were diluted and analyzed by the LIAISON® N-TACT® PTH Gen II assay following CLSl EP6-A. The results were analyzed by a weighed Deming regression of Observed PTH Concentration versus Expected PTH Concentration.

The resulting equations for each sample types are: Serum: Observed $\mathsf { P T H } = 0 . 9 7 6 7 x \cdot 3 . 6 2 4$ •• $\mathsf { R } ^ { 2 } = 0 . 9 9 8 2$ SST Serum: Observed $\mathsf { P T H } = 0 . 9 7 4 2 \times + 3 . 8 5 6$ . $\mathsf { R } ^ { 2 } = 0 . 9 9 8 7$ EPY EDTA plasma: Observed $\mathsf { P T H } = 1 . 0 1 2 \mathsf { x } - 4 . 1 2 7$ $\mathsf { R } ^ { 2 } = 0 . 9 9 8 3$ EY Lithium Heparin plasma: Observed PT $H = 0 . 9 4 6 1 x + 3 . 6 9 6$ . $R ^ { 2 } = 0 . 9 9 9 2$

# High Dose Hook Effect

Testing was conducted to determine if the LIAISON® N-TACT® PTH Gen II assay is susceptible to artificially low results in the presence of very high levels of PTH (Hook Effect). A zero sample was spiked with enough 1-84 PTH to equal concentrations above the assay measuring range of 1900 pg/mL.

No hook effect was observed up to 1,000,000 pg/mL of PTH.

# Recovery Study

Five (5) high concentration EDTA plasma samples and 5 low concentration samples EDTA plasma samples were analyzed neat on the LIAISON® N-TACT® PTH Gen II assay. Recovery samples were then prepared by mixing defined ratios of the high and low samples and tested in replicates of 5. The observed values were compared to the expected values to determine the $\%$ recovery.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Defined</td><td rowspan=1 colspan=1>Expected</td><td rowspan=1 colspan=1>Observed</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>High Sample 1 (HS1)2 HS1 : 1 LS11 HS1 : 1 LS11 HS1 : 2 LS1Low Sample 1 (LS1)</td><td rowspan=1 colspan=1>99979.8</td><td rowspan=1 colspan=1>695539383</td><td rowspan=1 colspan=1>674523358</td><td rowspan=1 colspan=1>97%97%93%</td></tr><tr><td rowspan=1 colspan=1>High Sample 2 (HS2)2 HS2 : 1 LS21 HS2 : 1 LS21 HS2 : 2 LS2Low Sample 2 (LS2)</td><td rowspan=1 colspan=1>1416164</td><td rowspan=1 colspan=1>1003790577</td><td rowspan=1 colspan=1>992794590</td><td rowspan=1 colspan=1>99%100%102%</td></tr><tr><td rowspan=1 colspan=1>High Sample 3 (HS3)2 HS3 : 1 LS31 HS3 : 1 LS31 HS3 : 2 LS3Low Sample 3 (LS3)</td><td rowspan=1 colspan=1>69637.7</td><td rowspan=1 colspan=1>479367255</td><td rowspan=1 colspan=1>495369237</td><td rowspan=1 colspan=1>103%101%93%</td></tr><tr><td rowspan=1 colspan=1>High Sample 4 (HS4)2 HS4 : 1 LS41 HS4 : 1 LS41 HS4 : 2 LS4Low Sample 4 (LS4)</td><td rowspan=1 colspan=1>1630248</td><td rowspan=1 colspan=1>1174939704</td><td rowspan=1 colspan=1>1118906668</td><td rowspan=1 colspan=1>95%96%95%</td></tr><tr><td rowspan=1 colspan=1>High Sample 5 (HS5)2 HS5 : 1 LS51 HS5 : 1 LS51 HS5 : 2 LS5Low Sample 5 (LS5)</td><td rowspan=1 colspan=1>46.44.7</td><td rowspan=1 colspan=1>32.625.518.4</td><td rowspan=1 colspan=1>30.323.818.4</td><td rowspan=1 colspan=1>93%93%100%</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Mean Recovery</td><td rowspan=1 colspan=1>97%</td></tr></table>

Analytical Specificity Cross-Reactivity Studies CLSI Guideline EP7-A2, Interference Testing in Clinical Chemistry; Approved Guideline; Second Edition.

Controlled studies of potentially cross-reacting substances were performed on the LIAISON® N-TACT® PTH Gen I assay at the concentrations listed below.

<table><tr><td rowspan=1 colspan=1>Cross-Reactant</td><td rowspan=1 colspan=1>SpikedConcentration</td><td rowspan=1 colspan=1>% CrossReactivity</td></tr><tr><td rowspan=1 colspan=1>PTH(7-84)</td><td rowspan=1 colspan=1>1200 pg/mL</td><td rowspan=1 colspan=1>53%</td></tr><tr><td rowspan=1 colspan=1>PTH(1-34)</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH (39 -68)</td><td rowspan=1 colspan=1>200,000 pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH(44-68</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH(39 84</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>PTH(53-84)</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>Calcitonin</td><td rowspan=1 colspan=1>200,000pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>C-Telopeptide (β crosslaps)</td><td rowspan=1 colspan=1>200,000pg/ml</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr><tr><td rowspan=1 colspan=1>Osteocalcin</td><td rowspan=1 colspan=1>200,000 pg/mL</td><td rowspan=1 colspan=1>&lt; 0.01%</td></tr></table>

Interference Studies Controlled studies of potentially interfering endogenous substances performed in EDTA plasma at two PTH levels (70 and $1 5 0 \ p g / \mathrm { m L } )$ showed no interference in the

LIAISON® N-TACT® PTH Gen II at the highest concentration for each substance listed below.

<table><tr><td rowspan=1 colspan=1>Drug/Substance</td><td rowspan=1 colspan=1>Concentration at which nosignificant interference(2 ±10%) was observed</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>40mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>3,000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>12 g/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>2760 ng/ml</td></tr><tr><td rowspan=1 colspan=1>HAMA</td><td rowspan=1 colspan=1>611.8 IU/mL</td></tr></table>

Controlled studies of potentially interfering exogenous substances performed in EDTA plasma at two PTH levels (70 and150 pg/mL) showed no interference in the LIAISON® N-TACT® PTH Gen II assay.

<table><tr><td rowspan=1 colspan=1>Drug/Substance</td><td rowspan=1 colspan=1>Concentration atwhich no significantinterference (≥ ±10%)was observed.</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>0.2 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>0.65 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Salicylic Acid</td><td rowspan=1 colspan=1>0.6 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>0.5 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Alendronate</td><td rowspan=1 colspan=1>0.08 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Etidronate</td><td rowspan=1 colspan=1>1.05 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Pamidronate</td><td rowspan=1 colspan=1>0.18 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Risedronate</td><td rowspan=1 colspan=1>0.06 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Vitamin D2</td><td rowspan=1 colspan=1>240 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Vitamin D3</td><td rowspan=1 colspan=1>240 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Calcitriol</td><td rowspan=1 colspan=1>1 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Alfacalcidol</td><td rowspan=1 colspan=1>2.5 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>1 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Calcium Acetate</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>CalciumCitrate</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>MagnesiumChloride</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>AluminumSulfate</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Lanthanum Chloride</td><td rowspan=1 colspan=1>0.4 mg/mL</td></tr></table>

# Limit of Blank. Limit of Detection and Limit of Quantitation

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined according to CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline June 2012- Second Edition.

The oloig imits were detei with the LIAISON® N-TACT® TH Gen I Asy   

<table><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>≤ 0.5 pg/mL</td><td rowspan=1 colspan=1>1.5 pg/ml</td><td rowspan=1 colspan=1>3.0 pg/mL</td></tr></table>

Stability   

<table><tr><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=2>Storage Conditions</td><td rowspan=1 colspan=1>Claimed stability</td></tr><tr><td rowspan=1 colspan=1>Reagent Integral</td><td rowspan=1 colspan=1>Open vial</td><td rowspan=1 colspan=1>on system</td><td rowspan=1 colspan=1>56 days</td></tr><tr><td rowspan=2 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Open vial - Reconstituted</td><td rowspan=1 colspan=1>on system</td><td rowspan=1 colspan=1>8 hours</td></tr><tr><td rowspan=1 colspan=1>Open vial - Reconstituted</td><td rowspan=1 colspan=1>2-8C</td><td rowspan=1 colspan=1>48 hours</td></tr><tr><td rowspan=1 colspan=1>Calibration curve</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>28 days</td></tr><tr><td rowspan=2 colspan=1>Controls</td><td rowspan=1 colspan=1>Open vial - Reconstituted</td><td rowspan=1 colspan=1>Room temp</td><td rowspan=1 colspan=1>7 hours</td></tr><tr><td rowspan=1 colspan=1>Open vial - Reconstituted</td><td rowspan=1 colspan=1>2-8C</td><td rowspan=1 colspan=1>8 hours</td></tr><tr><td rowspan=2 colspan=1>Calibration Verifiers</td><td rowspan=1 colspan=1>Open vial - Reconstituted</td><td rowspan=1 colspan=1>Room temp</td><td rowspan=1 colspan=1>7 hours</td></tr><tr><td rowspan=1 colspan=1>Open vial - Reconstituted</td><td rowspan=1 colspan=1>2-8C</td><td rowspan=1 colspan=1>8 hours</td></tr></table>

# Traceability

The LIAISON® N-TACT® PTH Gen II Calibrators, Controls and Calibration Verifiers are traceable to an in-house standard preparation referenced to the WHO International standard, PTH human recombinant, NIBSC 95/646.

# Value Assignment

# Calibrators

A minimum of 5 vials of each level of calibrator are tested on a minimum of 3 LIAlSON® XL Analyzers, in a minimum of 5 assay runs with six replicates per vial resulting in a minimum of 30 individual replicate results per calibrator level for final value assignment.

# Controls

A minimum of 10 vials of each level of control are tested on 2 different LIAlSON® N-TACT® PTH Gen II assay kit lots on a minimum of 3 LIAISON® XL Analyzers, in a minimum of 5 assay runs with 4 replicates per vial resulting in a minimum of 40 individual replicate results per control level for final value assignment.

# Calibration Verifiers

A minimum of 12 vials of each level of calibration verifier are tested on 2 different LIAISON® N-TACT® PTH Gen I assay kit lots on a minimum of 4 LIAISON® XL Analyzers, in a minimum of 6 assay runs with 4 replicates per vial resulting in a minimum of 48 individual replicate results per control level for final value assignment.

# 13. Conclusion:

The LIAISON® N-TACT® PTH Gen II, LIAISON® N-TACT® PTH Gen II Control Set and the LIAISON® N-TACT® PTH Gen II Calibration Verifiers are substantially equivalent in principle and performance to the Siemens ADVIA® CENTAUR INTACT Parathyroid Hormone (iPTH) Assay, the LIAISON® N-TACT® PTH Control Set and the LIAISON® N-TACT® PTH CliatonVrs iy

# November 8. 2013

DiaSorin Inc.   
Ms. Carol A. DePouw   
1951 Northwestern Ave.   
P.O. Box 285   
STILLWATER MN 55082-0285

Re: K132515 Tradc/Device Name: Liaison n-Tact PtH Gen II. Liaison N-Tact ptH Gen II Control Sct. LlAISON N-TACT PTH Gen II Calibration Verifiers Regulation Nunber: 21 CFR 862.1545 Regulation Name: Parathyroid hormone test system Regulatory Class: 11 Product Code: CEW. JJX Dated: October 23. 2013 Received: October 25. 2013

Dear Ms. DePouw:

We have reviewed your Section $5 ! 0 ( k )$ premarkel notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976. the enactment date of the Medical Device Amendments. or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device. subject to the general controls provisions of the Act. The general controls provisions of the Acl include requirements for annual registration. listing of devices. good manufacturing practice. labeling. and prohibitions against misbranding and adulteration. Please note: CDRH docs not evaluate information related to contract liability warranties. We remind you. however. that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class I1 (Special Controls) or class Il1 (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination docs not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements. including. but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable. the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Intemet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (2] CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Carol C. Benson -S for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

LIAISON® N-TACT PTH Gen II LiaiSOn® N-TACt® PtH Gen II Control Set LIAISON N-TACT® PTH Gen II Calibration Verifiers

Indications for Use (Describe)

The LIAISON® N-TACT® PTH Gen II is an in vilro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of intact human parathyroid hormone in serum, EDTA and Lithium Heparin plasma samples. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from disorders of calcium metabolism. The test is to be performed on the LIAISON XL analyzer.

The LIAISON® N-TACT® PTH Gen II Control Set is intended for use as assayed quality control samples to monitor the accuracy and precision of the DiaSorin LIAISON®   
N-TACT® PTH Gen II assSay.

The LIAISON® N-TACT PTH Gen II Calibration Verifiers are assayed quality control materials intended for the quantitative verification of calibration and reportable range of the LlAlSON® NTACT® PTH Gen II assay.